Detection of pancreatic cancer using antibody microarray-based serum protein profiling

Johan Ingvarsson, Christer Wingren, Anders Carlsson, Peter Ellmark, Britta Wahren, Gunilla Engström, Ulrika Harmenberg, Morten Krogh, Carsten Peterson, Carl Borrebaeck

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

104 Citeringar (SciVal)


The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of <12 months. Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures.
Sidor (från-till)2211-2219
StatusPublished - 2008

Ämnesklassifikation (UKÄ)

  • Immunologi inom det medicinska området
  • Biofysik


Utforska forskningsämnen för ”Detection of pancreatic cancer using antibody microarray-based serum protein profiling”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här